RESEARCH ARTICLE
Comparison of Treatment Safety and Patient Survival in Elderly versus Nonelderly Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib Combined with Transarterial Chemoembolization: A Propensity Score Matching Study Hao Hu1, Zhenhua Duan2, Xiaoran Long3, Yancu Hertzanu4, Xiaoqiang Tong5, Xiaoquan Xu6, Haibin Shi1, Sheng Liu1, Zhengqiang Yang1* 1 Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, 2 Chengdu Center for Disease Control and Prevention, Chengdu, China, 3 School of Pharmacy, Anhui Medical University, Hefei, China, 4 Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel, 5 Department of Interventional Radiology and Vascular Surgery, Peking University First Hospital, Beijing, China, 6 Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China * [email protected]
OPEN ACCESS Citation: Hu H, Duan Z, Long X, Hertzanu Y, Tong X, Xu X, et al. (2015) Comparison of Treatment Safety and Patient Survival in Elderly versus Nonelderly Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib Combined with Transarterial Chemoembolization: A Propensity Score Matching Study. PLoS ONE 10(2): e0117168. doi:10.1371/ journal.pone.0117168 Received: July 10, 2014
Abstract Aims This retrospective study was carried out to compare the outcomes between elderly (70 years of age) and nonelderly patients (
Comparison of Treatment Safety and Patient Survival in Elderly versus Nonelderly Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib Combined with Transarterial Chemoembolization: A Propensity Score Matching Study Hao Hu1, Zhenhua Duan2, Xiaoran Long3, Yancu Hertzanu4, Xiaoqiang Tong5, Xiaoquan Xu6, Haibin Shi1, Sheng Liu1, Zhengqiang Yang1* 1 Department of Interventional Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, 2 Chengdu Center for Disease Control and Prevention, Chengdu, China, 3 School of Pharmacy, Anhui Medical University, Hefei, China, 4 Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel, 5 Department of Interventional Radiology and Vascular Surgery, Peking University First Hospital, Beijing, China, 6 Department of Radiology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China * [email protected]
OPEN ACCESS Citation: Hu H, Duan Z, Long X, Hertzanu Y, Tong X, Xu X, et al. (2015) Comparison of Treatment Safety and Patient Survival in Elderly versus Nonelderly Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib Combined with Transarterial Chemoembolization: A Propensity Score Matching Study. PLoS ONE 10(2): e0117168. doi:10.1371/ journal.pone.0117168 Received: July 10, 2014
Abstract Aims This retrospective study was carried out to compare the outcomes between elderly (70 years of age) and nonelderly patients (
